Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ZIO-101
Darinaparson · 4 trials · 7 indications
| Arm | Type | Description |
|---|---|---|
| Single Arm | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Darinaparson | DRUG | 420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest for up to six months |
| ZIO-101 (Darinaparsin) | DRUG | IV zio-101 (Darinaparsin) give for 5 consecutive days to be repeated every 28 days for up to 6 months |
Inclusion Criteria 1. Subjects with a confirmed diagnosis of active multiple myeloma with measurable protein criteria present to evaluate response. Measurable disease is defined as having at least one of the following criteria within 28 days prior to registration: 1. Serum M-protein level \> 0....
Top 20 of 25 competitors
Darinaparson is an investigational small molecule being studied for the treatment of multiple myeloma, a cancer of plasma cells in the bone marrow. It has been evaluated in a Phase 2 clinical trial in patients with advanced multiple myeloma. It is not an approved therapy and remains in clinical development.
Darinaparson is being developed by Alaunos Therapeutics, Inc., which trades under the ticker TCRT. The company sponsored the Phase 2 clinical trial of the drug in advanced multiple myeloma conducted in the United States.
Darinaparson is in Phase 2 development. One Phase 2 trial has been completed, and no trials are currently active. The completed study was an uncontrolled, non-randomized, open-label trial that enrolled 17 patients with advanced multiple myeloma.
Darinaparson has been studied in one clinical trial, NCT00423644, titled A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b. The trial was a completed Phase 2 study conducted in the United States that enrolled 17 patients aged 18 years and older.
Yes, Darinaparson is also known as ZIO-101. The Phase 2 trial in advanced multiple myeloma was conducted under the name ZIO-101, so searches for either name refer to the same investigational small molecule developed by Alaunos Therapeutics.